Alland Leila 4
4 · PMV Pharmaceuticals, Inc. · Filed Sep 8, 2021
Insider Transaction Report
Form 4
Alland Leila
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-09-07$3.90/sh+3,900$15,210→ 3,900 total - Sale
Common Stock
2021-09-07$30.25/sh−3,900$117,975→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-09-07−3,900→ 353,950 totalExercise: $3.90Exp: 2030-02-04→ Common Stock (3,900 underlying)
Footnotes (2)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
- [F2]One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.